» Articles » PMID: 33441142

On the Role of Bacterial Metalloproteases in COVID-19 Associated Cytokine Storm

Overview
Publisher Biomed Central
Date 2021 Jan 14
PMID 33441142
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The cytokine release syndrome or cytokine storm, which is the hyper-induction of inflammatory responses has a central role in the mortality rate of COVID-19 and some other viral infections. Interleukin-6 (IL-6) is a key player in the development of cytokine storms. Shedding of interleukin-6 receptor (IL-6Rα) results in the accumulation of soluble interleukin-6 receptors (sIL-6R). Only relatively few cells express membrane-bound IL-6Rα. However, sIL-6R can act on potentially all cells and organs through the ubiquitously expressed gp130, the coreceptor of IL-6Rα. Through this, so-called trans-signaling, IL-6-sIL-6R is a powerful factor in the development of cytokine storms and multiorgan involvement. Some bacteria (e.g., Serratia marcescens, Staphylococcus aureus, Pseudomonas aeruginosa, Listeria monocytogenes), commonly considered to cause co-infections during viral pneumonia, can directly induce the shedding of membrane receptors, including IL-6Rα, or enhance endogenous shedding mechanisms causing the increase of sIL-6R level. Here we hypothesise that bacteria promoting shedding and increase the sIL-6R level can be an important contributing factor for the development of cytokine storms. Therefore, inhibition of IL-6Rα shedding by drastically reducing the number of relevant bacteria may be a critical element in reducing the chance of a cytokine storm. Validation of this hypothesis can support the consideration of the prophylactic use of antibiotics more widely and at an earlier stage of infection to decrease the mortality rate of COVID-19. Video abstract.

Citing Articles

What do we know about IL-6 in COVID-19 so far?.

Jiang J, Wang J, Yao L, Lai S, Zhang X Biophys Rep. 2023; 7(3):193-206.

PMID: 37287491 PMC: 10244797. DOI: 10.52601/bpr.2021.200024.


Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells.

Arjmand B, Alavi-Moghadam S, Sarvari M, Rezaei-Tavirani M, Rezazadeh-Mafi A, Arjmand R Inflammopharmacology. 2023; 31(1):171-206.

PMID: 36600055 DOI: 10.1007/s10787-022-01132-6.


Amyloidogenesis: What Do We Know So Far?.

Alraawi Z, Banerjee N, Mohanty S, Kumar T Int J Mol Sci. 2022; 23(22).

PMID: 36430450 PMC: 9695042. DOI: 10.3390/ijms232213970.


Evaluating the structural and immune mechanism of Interleukin-6 for the investigation of goat milk peptides as potential treatments for COVID-19.

Bhavaniramya S, Sibiya A, Alothaim A, Othaim A, Ramar V, Veluchamy A J King Saud Univ Sci. 2022; 34(4):101924.

PMID: 35233153 PMC: 8875951. DOI: 10.1016/j.jksus.2022.101924.

References
1.
Cheung C, Poon L, Lau A, Luk W, Lau Y, Shortridge K . Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet. 2002; 360(9348):1831-7. DOI: 10.1016/s0140-6736(02)11772-7. View

2.
Lan S, Lai C, Huang H, Chang S, Lu L, Hsueh P . Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020; 56(3):106103. PMC: 7377685. DOI: 10.1016/j.ijantimicag.2020.106103. View

3.
Johnson D, OKeefe R, Grandis J . Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018; 15(4):234-248. PMC: 5858971. DOI: 10.1038/nrclinonc.2018.8. View

4.
Hunter C, Jones S . IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015; 16(5):448-57. DOI: 10.1038/ni.3153. View

5.
Ferreira M, Matheson M, Duffy D, Marks G, Hui J, Le Souef P . Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. 2011; 378(9795):1006-14. PMC: 3517659. DOI: 10.1016/S0140-6736(11)60874-X. View